Graft vs. Host Discussion
Claim This Podcastby Graft vs. Host Discussion
Podcast Overview
<p>The landscape of graft-versus-host disease (GVHD) management is continuously evolving. Graft vs. Host Discussion is a series of in-depth conversations with experts on the front lines of all facets of chronic GVHD. We are delving into the most pressing topics, ranging from key clinical data to practical clinical pearls and long-term complications of chronic GVHD. We are starting the conversation with experts at the forefront of this disease's research and management; they provide a comprehensive perspective on patient management and care to fellow healthcare professionals equally committed to improving and personalizing treatment for patients with GVHD.</p><p>This podcast is intended for healthcare professionals only. Speaker disclosures are available in each episode’s notes. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing any product, always refer to the latest Product Monograph. Financial support for the Graft vs. Host Discussion program was provided by Sanofi Canada.</p><p>MAT-CA-2301273 App Sept 2023</p>
Language
🇺🇲
Publishing Since
8/29/2023
Reach the team behind Graft vs. Host Discussion
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
February 9, 2026
The cGVHD Q&A: Expert Insights in Chronic GVHD Management
<p>This special FAQ episode brings together <strong>Dr. Dennis Kim,</strong> Hematologist/Oncologist, and <strong>Dr. Gizelle Popradi</strong>, Hematologist, for an in-depth conversation on what clinicians need to know about cGVHD management.</p><p>Our experts offer an insightful overview of the <strong>evolving frontline algorithm in cGVHD management</strong>, including how to select patients for systemic steroids and when to reassess for non-response. They highlight how <strong>emerging therapeutic agents </strong>are shaping sequential treatment decisions and provide practical guidance on multidisciplinary care and proactive monitoring for multi-organ involvement and early pulmonary changes. The experts also emphasize the importance of incorporating <strong>patient-reported outcomes</strong> into clinical practice.</p><p>Tune in to explore <strong>clinical pearls</strong> on prevention, guideline integration, and evidence-based algorithms, delivering actionable insights to support more patient-centred care.</p><p><strong>Don’t miss the conversation!</strong> </p><p>The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. </p><p><strong>Declaration of conflict of interest:</strong> </p><p><strong>Dr. Gizelle Popradi:</strong></p><p>· Direct financial relationship, including receipt of honoraria: AbbVie, Amgen, BMS, Daiichi Sankyo, Gilead, Incyte, Jazz, Kyowa Kirin, Mallinckrodt/Therakos, Medexus, Novartis, Paladin, Pfizer, Sanofi, Sean Gen, Servier, Sobi, Takeda.</p><p><strong>Dr. Dennis Kim:</strong></p><p>· Direct financial relationship, including receipt of honoraria: Novartis, Sanofi, Jazz, Paladin. Membership on advisory boards or speaker bureaus: Novartis, Sanofi, Jazz, Paladin. Funded grants, research, or clinical trials: Novartis, Sanofi, Jazz, Paladin. </p><p>MAT-CA-2501632</p>
October 6, 2025
Bridging pediatric and adult cGVHD care
<p>When it comes to managing chronic graft-versus-host disease (cGVHD), what are the unique considerations for pediatric patients, setting them apart from adult care? </p><p>Our host, <strong>Dr. Kirk Schultz</strong>, explores this and other topics with<strong> Dr. Henrique Bittencourt</strong>, a pediatric hematologist/oncologist and clinical professor at the CHU Sainte-Justine, Université de Montréal. </p><p>Join our experts as they navigate the <strong>distinct landscape</strong> of <strong>chronic GVHD in children</strong>. They explore why <strong>pediatric presentations</strong> often require <strong>unique diagnostic approaches</strong> and <strong>specialized management strategies</strong>, emphasizing the critical role of <strong>multidisciplinary collaboration</strong> and addressing the <strong>challenges of transitioning</strong> patients to <strong>adult care</strong>. </p><p><strong>Don’t miss the conversation!</strong> </p><p>The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. </p><p></p><p><strong>Declaration of conflict of interest:</strong> </p><p><strong>Dr. Kirk Schultz:</strong> </p><p>· Membership on advisory board or speakers’ bureaus: Incyte, Sanofi. Patents on a drug, product, or device: cGvHD diagnostic and risk assignment algorithms. </p><p><strong>Dr. Henrique Bittencourt:</strong> </p><p>· Direct financial relationship, including receipt of honoraria: Jazz. Membership on advisory board or speakers' bureaus: Amgen, Incyte, Jazz, Sanofi. Funded grants, research, or clinical trials: Amgen, AbbVie, Incyte, Novartis, Roche, Sanofi, Syndax. </p><p> </p><p>MAT-CA-2501035 </p>
September 10, 2025
Collaborative care for ocular GVHD
<p>How can we best alleviate the significant impact of ocular chronic graft-versus-host disease (cGVHD) on our patients' daily lives and overall well-being?</p><p>Our host, <strong>Dr. Kareem Jamani</strong>, explores this and other topics with<strong> Dr. Jamie Bhamra</strong>, an ophthalmologist specialized in corneal and ocular surface diseases, and Assistant Professor at the University of Calgary.</p><p>This episode features our experts delving into the <strong>frequent presentations</strong> of ocular GVHD, the <strong>burden</strong> this manifestation places on transplant patients, and the <strong>importance of collaborative care</strong> among multidisciplinary specialists to <strong>optimize patient outcomes</strong>. They also discuss a <strong>multipronged management approach</strong>, from initial treatments to advanced interventions for this common, yet sometimes challenging, complication.</p><p><strong>Declaration of conflict of interest:</strong> </p><p><strong>Dr. Kareem Jamani:</strong></p><ul><li>Membership on advisory board or speakers’ bureaus: Jazz, Novartis, Paladin, Sanofi, Servier, Takeda, Vertex. Funded grants, research, or clinical trials: Jazz. </li></ul><p><strong>Dr. Jamie Bhamra:</strong></p><ul><li>None.</li></ul><p><strong>Don’t miss the conversation!</strong> </p><p>The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. </p><p><strong>Declaration of conflict of interest:</strong> </p><p>MAT-CA-2500984</p>
12 total episodes available
Deep-dive analytics for Graft vs. Host Discussion
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Graft vs. Host Discussion?
<p>The landscape of graft-versus-host disease (GVHD) management is continuously evolving. Graft vs. Host Discussion is a series of in-depth conversations with experts on the front lines of all facets of chronic GVHD. We are delving into the most pressing topics, ranging from key clinical data to practical clinical pearls and long-term complications of chronic GVHD. We are starting the conversation with experts at the forefront of this disease's research and management; they provide a comprehensive perspective on patient management and care to fellow healthcare professionals equally committed to improving and personalizing treatment for patients with GVHD.</p><p>This podcast is intended for healthcare professionals only. Speaker disclosures are available in each episode’s notes. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing any product, always refer to the latest Product Monograph. Financial support for the Graft vs. Host Discussion program was provided by Sanofi Canada.</p><p>MAT-CA-2301273 App Sept 2023</p> - How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 7 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.